Can pembrolizumab (pembrolizumab) be used to treat a female patient with serous adenocarcinoma involving the female genitalia, who has a history of kidney transplant and a recent perigraft renal abscess?

Pembrolizumab Use in Serous Adenocarcinoma with Kidney Transplant History

Pembrolizumab should NOT be used in this patient with a history of kidney transplant, as solid organ transplant recipients requiring immunosuppression are explicitly excluded from clinical trials and face prohibitive risks of graft rejection and life-threatening complications that far outweigh any potential oncologic benefit.

Critical Contraindication: Solid Organ Transplantation

The FDA label for pembrolizumab explicitly excludes patients with "a medical condition that required immunosuppression" from clinical trials 1. This exclusion is absolute and applies directly to kidney transplant recipients who require chronic immunosuppressive therapy to maintain graft function.

Mechanism of Incompatibility

• Pembrolizumab is a PD-1 inhibitor that activates T-cell-mediated immune responses, which is fundamentally incompatible with the immunosuppression required to prevent transplant rejection 2
• The drug induces systemic, nonspecific immunostimulatory responses leading to proinflammatory cytokine secretion, which would directly antagonize anti-rejection medications 2
• Immune checkpoint inhibitors restore T-cell activity, creating a high-probability scenario for acute allograft rejection that could result in graft loss and need for dialysis 3

Additional Risk: Recent Perigraft Renal Abscess

The recent perigraft renal abscess compounds the contraindication:

• Active or recent serious infection in an immunocompromised transplant recipient represents an unstable baseline that would be further destabilized by pembrolizumab's immune activation 1
• Pembrolizumab can cause serious treatment-related adverse events in 8-13% of patients, including infections and fever, which would be particularly dangerous in this setting 2
• The patient's ability to fight infection while on immunosuppression is already compromised, and adding an immune checkpoint inhibitor creates unpredictable and potentially catastrophic immune dysregulation

Oncologic Context: Serous Adenocarcinoma of Female Genitalia

While pembrolizumab has demonstrated activity in certain gynecologic malignancies, the transplant status supersedes any potential benefit:

Limited Evidence for Serous Carcinomas

• For uterine serous carcinoma, pembrolizumab may be considered only if the tumor is MSI-H/dMMR or has high tumor mutational burden (TMB-H) 4, 5, 6
• A case report showed durable response in MSI-H uterine serous carcinoma with Lynch syndrome, but this patient had no contraindications to immunotherapy 7
• In high-grade serous ovarian carcinoma, pembrolizumab combined with chemotherapy showed feasibility but was discontinued in 23% of patients due to adverse events in immunocompetent patients 8

Biomarker Testing Would Be Futile

Even if the tumor were MSI-H/dMMR or TMB-H (which would normally indicate pembrolizumab responsiveness 5, 6, 9), the transplant status creates an absolute contraindication that cannot be overcome by favorable tumor biology.

Alternative Management Strategy

The patient should be managed with conventional chemotherapy or hormonal therapy (if low-grade endometrioid histology) that does not interfere with immunosuppression:

• For serous carcinomas, platinum-based chemotherapy (carboplatin/paclitaxel) remains the standard approach 4
• Bevacizumab may be considered for recurrent disease in patients who have progressed on cytotoxic chemotherapy, as it does not activate T-cell responses 4
• Coordinate closely with transplant nephrology to adjust immunosuppression as needed during chemotherapy to balance infection risk and graft protection

Common Pitfall to Avoid

Do not be tempted to use pembrolizumab even if tumor testing reveals MSI-H, dMMR, or TMB-H status. While these biomarkers predict response in eligible patients 5, 6, 9, solid organ transplantation represents a hard stop that cannot be negotiated. The risk of losing a functioning kidney transplant and requiring lifelong dialysis, combined with potential sepsis from immune dysregulation in the setting of recent abscess, creates a mortality risk that vastly exceeds any potential survival benefit from pembrolizumab.